BiotechTube

Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution

ApprovedWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Peritoneal Dialysis

Conditions

Peritoneal Dialysis, Hypertriglyceridemia

Trial Timeline

Nov 1, 2006 → Jun 1, 2007

NCT ID
NCT00397358

About Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution

Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution is a approved stage product being developed by Baxter for Peritoneal Dialysis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00397358. Target conditions include Peritoneal Dialysis, Hypertriglyceridemia.

What happened to similar drugs?

2 of 6 similar drugs in Peritoneal Dialysis were approved

Approved (2) Terminated (0) Active (4)
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
✅ertapenemMerckApproved
🔄PA21Kissei PharmaceuticalPhase 3
🔄Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3
✅Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00397358ApprovedWithdrawn

Competing Products

20 competing products in Peritoneal Dialysis

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
MCY-M11 + CyclophosphamideMaxCytePhase 1
11
R744 + R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
AbemaciclibEli LillyPhase 1
36
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)AbbViePhase 1/2
32
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLDAstraZenecaPhase 2
35
Tremelimumab + OlaparibAstraZenecaPhase 1
21
ertapenemMerckApproved
43
Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + PlaceboNovartisPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2PfizerPhase 1/2
24
Bevacizumab + Nivolumab + RucaparibBristol Myers SquibbPhase 2
39
IniparibSanofiPhase 2
35
Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3
40
nanoliposomal irinotecanIpsenPhase 1
26
Anti-Adhesion ProductBaxterPhase 2
32
PioglitazoneBaxterPre-clinical
23
Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved
47
RadspherinOncoinventPhase 2
32